Table 3.

Association of Treatment Arm and Baseline Characteristics With PSA Response

PSA Comparison (ng/mL)	Univariable			Multivariable
	OR	95% CI	P	OR	95% CI	P
Treatment (AD plus cixutumumab v AD)
≤ 0.2 v > 4.0	1.50	0.83 to 2.73	.18	1.40	0.70 to 2.78	.34
> 0.2 to ≤ 4.0 v > 4.0	1.38	0.62 to 3.06	.43	1.48	0.63 to 3.44	.37
Age, years*
≤ 0.2 v > 4.0	1.15	1.01 to 1.35	.04	1.21	1.02 to 1.44	.03
> 0.2 to ≤ 4.0 v > 4.0	1.05	0.87 to 1.27	.62	1.07	0.87 to 1.31	.55
Log PSA at baseline
≤ 0.2 v > 4.0	0.67	0.55 to 0.81	< .001	0.67	0.54 to 0.83	< .001
> 0.2 to ≤ 4.0 v > 4.0	0.85	0.68 to 1.06	.15	0.83	0.65 to 1.06	.14
Gleason score (> 7 v < 7)
≤ 0.2 v > 4.0	0.47	0.14 to 1.58	.22
> 0.2 to ≤ 4.0 v > 4.0	0.74	0.14 to 4.10	.73
Performance status
≤ 0.2 v > 4.0	0.79	0.45 to 1.39	.42
> 0.2 to ≤ 4.0 v > 4.0	0.57	0.25 to 1.24	.17
Bone pain (no v yes)
≤ 0.2 v > 4.0	6.17	2.83 to 13.44	< .001	5.09	2.23 to 11.60	< .001
> 0.2 to ≤ 4.0 v > 4.0	4.08	1.54 to 10.84	.005	3.63	1.35 to 9.79	.01
Site of metastasis (nonvisceral v visceral)
≤ 0.2 v > 4.0	1.32	0.57 to 3.07	.52
> 0.2 to ≤ 4.0 v > 4.0	1.40	0.44 to 4.51	.57
BMI (obese v normal weight)
≤ 0.2 v > 4.0	2.05	0.93 to 4.52	.07
> 0.2 to ≤ 4.0 v > 4.0	2.09	0.70 to 6.27	.19

Abbreviations: AD, androgen deprivation; BMI, body mass index; OR, odds ratio; PSA, prostate-specific antigen.

^*Five-year increment in age.